All Updates

All Updates

icon
Filter
Funding
Cardiosense raises USD 15.1 million in venture funding
Preventive Healthcare
Dec 15, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Preventive Healthcare

Preventive Healthcare

Dec 15, 2022

Cardiosense raises USD 15.1 million in venture funding

Funding

  • Cardiovascular disease detection provider Cardiosense raised USD 15.1 million in a venture funding round co-led by Hatteras Venture Partners and Broadview Ventures along with participation from other venture capital firms.

  • The raised funds will be used by the company to hire additional staff and speed up product development. The funds will also be used to carry out a clinical study on heart failure.

  • Post-funding the company will also appoint Jeff Terrell from Hatteras Venture Partners and Daniel Gottlieb from Broadview Ventures to the company’s board of directors.

  • Chicago-based Cardiosense is a developer of an AI-powered platform and devices used to identify predictive biomarkers that can help detect and manage heart disease. As of December 2022, the company has developed digital tools, multi-sensor devices, and an analysis algorithm for detecting early signs of cardiovascular disease, informing patient therapy, and improving patient outcomes. Cardiosense’s devices and platform currently focus on improving the management of congestive heart failure (CHF). 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.